Organization & Developments: Genzyme

Parents

2013: Global revenue expectations slashed for Genzymeâ™s Lemtrada (2013)
2014: Genzyme to resubmit application to FDA for multiple sclerosis drug, Lemtrada
2019: VA_65--Genzyme Corporation dba Genzyme Therapeutics Division 65IB, 36F797D0153 Effective 5/15/2019 to 5/14/2024
4. Genzyme - $805M (€588M) 2010 R&D
Anormed
Genzyme
Genzyme Biosurgery
Genzyme, the world’s largest maker of medicines for rare genetic disorders, sells products less likely to face generic competitors because its treatments made from living cells are harder to copy than traditional pills made from chemical compounds
Leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, orthopedic and cardiovascular areas.
Products targeted on rare inherited disorders, kidney disease, orthopaedics, transplant and immune disease, cancer, and diagnost